Sigma Planning Corp Purchases Shares of 15,375 TG Therapeutics, Inc. $TGTX

Sigma Planning Corp purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,375 shares of the biopharmaceutical company’s stock, valued at approximately $845,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TGTX. Danske Bank A S bought a new stake in TG Therapeutics in the third quarter valued at approximately $25,000. EverSource Wealth Advisors LLC raised its holdings in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the last quarter. Truvestments Capital LLC lifted its position in shares of TG Therapeutics by 172.4% in the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics in the 4th quarter worth approximately $52,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $63.00.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $56.09 on Wednesday. The company has a market cap of $8.59 billion, a price-to-earnings ratio of 20.47, a price-to-earnings-growth ratio of 2.33 and a beta of 1.62. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $59.30. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The firm has a 50 day moving average of $53.41 and a 200-day moving average of $42.28.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s revenue was up 70.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.17 EPS. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.